Vyjuvek

beremagene geperpavec-svdt

Approval

ApplicationBLA 125774
Approval dateMay 19, 2023
Approval year2023
SponsorKrystal Biotech, Inc

FDA-approved use

For the treatment of wounds in adult and pediatric patients with dystrophic epidermolysis bullosa (DEB) with mutation(s) in the collagen type VII alpha 1 chain (COL7A1) gene

Approval package

Query with Claude

The fda-analyst skill answers natural-language questions about this approval by fetching the relevant FDA review PDFs at query time.

git clone https://github.com/cbetz/trove
cp -r trove/skills/fda-analyst ~/.claude/skills/

Example prompts for Vyjuvek: